Rapid, regiospecific syntheses of deuterium substituted 6-[18F]fluorodopamine (α,α-D2; β,β-D2 and α,α,β,β-D4) for mechanistic studies with positron emission tomography
✍ Scribed by Yu-Shin Ding; Joanna S. Fowler; Alfred P. Wolf
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- French
- Weight
- 521 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Doubly labeled (^18^F and deuterium) 6‐fluorodopamine (6‐FDA) isotopomers were prepared to probe the contribution of metabolism by monoamine oxidase (MAO) and dopamine β‐hydroxylase (DBH) on the kinetics of 6‐[^18^F]FDA in baboon heart. Specifically deuterated 6‐[^18^F]FDA‐α,α‐D~2~ and 6‐[^18^F]FDA‐β,β‐D~2~ were prepared by a six‐step synthesis starting from nucleophilic aromatic substitution with NCA [^18^F]fluoride on 6‐nitropiperonal or 6‐nitropiperonal‐D in a decay corrected radiochemical yield of 3‐10% (EOB). 6‐[^18^F]FDA‐α,α,β,β‐D~4~ was prepared in 4 steps in a radiochemical yield of 16‐20% (EOB) and specific activity 2‐5 Ci/μmol (EOB). The regiospecificity of deuterium substitution in the synthesis of 6‐[^18^F]FDA‐α,α,β,β‐D~4~ was verified using piperonal as a substrate.
📜 SIMILAR VOLUMES
The synthesis of the novel glucose conjugated O 6 -methylguanine-DNA methyltransferase (MGMT) inhibitor 2-amino-6-(2-[ 18 F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-a-D-glucosyl)-purine is reported. This compound might serve as a radiotracer for the determination of the MGMT status of tumour tissue.